During the corresponding time, Allurion Technologies Inc saw a revenue deteriorated by -42.9 % year on year, sequentially revenue fell by -20.93 %. While revenue at the Allurion Technologies Inc 's corporate clients
In the ever-evolving landscape of healthcare solutions, Allurion Technologies, Inc. (NYSE: ALUR) is poised to make significant strides in the battle against obesity. Based in Natick, Massachusetts, Allurion is a forward-thinking company dedicated to tackling this global health challenge. In a bold move that underscores its commitment to innovation, Allurion recently announced plans to initiate a clinical study combining its flagship product, the Allurion Balloon, with GLP-1 (Glucagon-like Peptide-1) agonists.The proposed combination therapy aims to leverage the strengths of both solutions to improve patient outcomes. The Allurion Balloon, a non-surgical weight loss device, provides a temporary gastric volume...
In a major milestone for the obesity treatment landscape, Allurion Technologies, Inc. (NYSE: ALUR) has unveiled promising topline results from its pivotal AUDACITY trial. This groundbreaking open-label, multicenter, randomized, controlled study is the first of its kind conducted in the United States to examine the efficacy and safety of an intragastric balloon for weight loss, while also reporting primary outcomes extending beyond nine months.The trial involved a significant cohort of 550 participants, each of whom received the Allurion Balloon. Participants took part in a rigorous evaluation process, designed to offer dependable insights into the long-term effectiveness of the balloon device. The results ob...
Allurion Technologies Advances Towards NYSE Compliance with Strategic Plan Approval Allurion Technologies, Inc. (NYSE: ALUR), a pioneering enterprise in the battle against obesity, has taken a significant step towards securing its future on the New York Stock Exchange (NYSE). The corporation recently publicized that it has received an Acceptance Letter from the Listings Operations Committee of the NYSE. This development comes as a strategic milestone in Allurion s journey to regain compliance with the NYSE’s continued listing standards, specifically the Minimum Market Capitalization Standard, as detailed in Section 802.01B of the NYSE Listed Company Manual.The acceptance of Allurion s compliance plan marks...
Revamping Weight Management: Allurion Unveils Insights from Massive Global Study at Obesity Week 2024 In a landmark presentation at The Obesity Society’s Annual Conference, Obesity Week 2024, Allurion Technologies, Inc. (NYSE: ALUR) unveiled groundbreaking findings from the largest-ever real-world study on obesity management. Based in Natick, Massachusetts, Allurion is a company passionately committed to combating obesity with innovative solutions. This year, they took centre stage with two pivotal abstracts that promise to reshape our understanding of weight management.The highlight of Allurion s presentation was data from an expansive cohort of 19,428 patients, spanning 72 countries who were treated betw...
NATICK, Mass. Allurion Technologies, Inc. (NYSE: ALUR), a pioneering company in the battle against obesity, has announced significant findings from a recent study published in the journal Clinical Obesity . The study sheds light on the effects of the Allurion Program, particularly focusing on weight reduction and body composition changes in patients who have undergone balloon therapy. Overview of the Allurion Program and Study DesignThe Allurion Program employs a novel approach to facilitate weight loss through a non-surgical gastric balloon designed for easy ingestion. Unlike traditional methods that require invasive procedures, the Allurion balloon expands in the stomach, promoting feelings of fullness...
In a significant development for Allurion Technologies, Inc. (NYSE: ALUR), the Massachusetts-based company specializing in innovative obesity solutions, has announced receipt of a notice from the New York Stock Exchange (NYSE) concerning its compliance with ongoing listing standards. The notification, issued recently, indicates that Allurion has fallen short of the minimum market capitalization requirement, which is set at $50 million, based on the average market capitalization calculated over a 30-trading day period ending August 29, 2024. This notice arrives during a challenging era for Allurion as it seeks to navigate both operational hurdles and the broader pressures of the financial markets. The company...
In a dynamic environment where technological innovation collides with regulatory scrutiny, Allurion Technologies, Inc. (NYSE: ALUR) is asserting its commitment to tackling obesity while simultaneously contending with challenges that could alter its trajectory in the market. Recent announcements from the company reveal both promising advancements in weight-loss outcomes and significant hurdles posed by regulatory requirements, particularly in France.The focal point of Allurion’s recent achievements is a study showcasing the effectiveness of the Allurion Program. This program involves a unique weight loss balloon system, complemented by virtual guidance and support. Findings from the study, which evaluated r...
Allurion Technologies Faces NYSE Listing Challenge Amid Prolonged Market Underperformance Natick, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a pioneering enterprise dedicated to combating obesity, recently revealed that it has received a written notice from the New York Stock Exchange (NYSE). The notice states that Allurion is not in compliance with the NYSE s continued listing standards. Specifically, the average closing price of the company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period ending on August 8, 2024.The NYSE’s notice comes at a time when Allurion’s shares are significantly trailing the overall market performance. Throughout the month, the perf...
Allurion Technologies, Inc., a prominent player in the fight against obesity, recently made significant developments by completing a successful public offering and achieving impressive preliminary results for the first quarter of 2024. These exciting developments showcase the company s dedication to its mission and highlight the potential for continued growth and innovation in the battle against obesity.Public Offering Success:Allurion Technologies recently announced the successful pricing of an underwritten public offering, raising a total of $17.3 million in gross proceeds. The offering involved 14,406,508 shares of the company s common stock, along with warrants to purchase an equal number of shares. Pric...
A Revolutionary Breakthrough: Allurion s Weight Loss Program Shows Unprecedented Lean Mass Gains in PatientsIn a ground-breaking study published by Allurion Technologies, Inc., a company committed to tackling the global epidemic of obesity, new data has emerged demonstrating significant lean mass gains in patients who experienced a remarkable 14% weight loss within a span of just four months. This cutting-edge research opens up new possibilities in the quest for sustainable weight loss and overall better health.The study observed a diverse group of patients enrolled in the Allurion Program. Utilizing state-of-the-art technology, including the Allurion App, Connected Scale, and Health Tracker, the participant...
Sources:
Allurion Technologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Allurion Technologies Inc’s corporate clients.
For your research, we’ve provided 9 tables on Allurion Technologies Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
19.41 %